Table 3. Bliss synergy assessment of cell killing by BCL-2 family inhibitors combined with docetaxel.

Breast cancer, NSCLC, and ovarian cancer cell lines were cultured in the presence of navitoclax, A-1155463, or venetoclax plus or minus docetaxel for 72 hours before assessing cell viability. The sum of Bliss scores across the combination dose matrix is listed for each cell line.

Cell
type
Cell
line
Bliss sums
Navitoclax +
docetaxel
A-1155463 +
docetaxel
Venetoclax +
docetaxel
Breast
cancer
(9 × 3
dose
matrix)
MDA-MB-231264277−159
MDA-MB-231 (LC3)253305−62
MDA-MB-175 (VII)−19290−130
HCC1806269224−46
MX-1−4353−10
HCC139580−31−109
HCC1428153−203−204
HCC386742−201
ZR-75-1271103−312
HCC1569193185−102
HCC150016514615
MCF-7 (Luc)10063−133
MDA-MB-36166110−40
SK-BR-383101−78
UAC812−105−269−210
BT-4745−5−43
HCC1187990−173
HCC1937220332−106
DU4475242229168
Hs578T9962−161
T-47D289250−219
ZR-75-30−290−265−418
BT-20126260−106
HCC2218−134−250−135
HCC159040−105−245
BT-54941117−76
HCC114345195−215
MDA-MB-436−110−96−386
NSCLC
(5 × 5
dose
matrix)
LXFL529656734236
SW15733544610
SKMES-117415280
A549144137−19
H1650335312146
H1975696−23
H129928030267
H2395976
H522195242−19
H66110994−54
H46012810515
H1568−2727−29
H83863128−6
EBC-1−107−10318
H17031296
Ovarian
cancer
(9 × 3
dose
matrix)
OVCAR-3635683−334
OVCAR-4−33−129−231
OVCAR-551170692
OVCAR-8247159−67
SKOV3487747−53
IGROV133−49−191